Fulcrum Therapeutics, Inc. (FULC): Price and Financial Metrics
FULC Price/Volume Stats
| Current price | $4.00 | 52-week high | $15.00 |
| Prev. close | $4.09 | 52-week low | $2.25 |
| Day low | $3.97 | Volume | 50,803 |
| Day high | $4.07 | Avg. volume | 1,420,253 |
| 50-day MA | $4.56 | Dividend yield | N/A |
| 200-day MA | $5.45 | Market Cap | 247.29M |
FULC Stock Price Chart Interactive Chart >
FULC POWR Grades
- Sentiment is the dimension where FULC ranks best; there it ranks ahead of 79.85% of US stocks.
- The strongest trend for FULC is in Value, which has been heading down over the past 177 days.
- FULC's current lowest rank is in the Stability metric (where it is better than 3.06% of US stocks).
FULC Stock Summary
- FULC's price/sales ratio is 84.72; that's higher than the P/S ratio of 97.62% of US stocks.
- Revenue growth over the past 12 months for FULCRUM THERAPEUTICS INC comes in at -78.97%, a number that bests merely 2.25% of the US stocks we're tracking.
- In terms of volatility of its share price, FULC is more volatile than 95.6% of stocks we're observing.
- If you're looking for stocks that are quantitatively similar to FULCRUM THERAPEUTICS INC, a group of peers worth examining would be ADVM, SPRO, DCPH, BPMC, and YMAB.
- FULC's SEC filings can be seen here. And to visit FULCRUM THERAPEUTICS INC's official web site, go to www.fulcrumtx.com.
FULC Valuation Summary
- FULC's price/earnings ratio is -2.6; this is 109.74% lower than that of the median Healthcare stock.
- Over the past 51 months, FULC's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for FULC.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| FULC | 2023-09-22 | 84.7 | 0.9 | -2.6 | -2.4 |
| FULC | 2023-09-21 | 83.1 | 0.9 | -2.6 | -2.3 |
| FULC | 2023-09-20 | 90.0 | 1.0 | -2.8 | -2.5 |
| FULC | 2023-09-19 | 87.6 | 1.0 | -2.7 | -2.5 |
| FULC | 2023-09-18 | 88.6 | 1.0 | -2.7 | -2.5 |
| FULC | 2023-09-15 | 91.2 | 1.0 | -2.8 | -2.6 |
FULC's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- FULC has a Quality Grade of D, ranking ahead of 14.4% of graded US stocks.
- FULC's asset turnover comes in at 0.108 -- ranking 260th of 681 Pharmaceutical Products stocks.
- 500 - Internal server error
The table below shows FULC's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.108 | 1 | -1.792 |
| 2021-03-31 | 0.090 | 1 | -1.731 |
| 2020-12-31 | 0.069 | 1 | -1.552 |
| 2020-09-30 | 0.037 | 1 | -2.003 |
| 2020-06-30 | 0.024 | 1 | -2.355 |
| 2020-03-31 | 0.008 | 1 | -3.830 |
FULC Price Target
For more insight on analysts targets of FULC, see our FULC price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $34.86 | Average Broker Recommendation | 1.5 (Moderate Buy) |
Fulcrum Therapeutics, Inc. (FULC) Company Bio
Fulcrum Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
Latest FULC News From Around the Web
Below are the latest news stories about FULCRUM THERAPEUTICS INC that investors may wish to consider to help them evaluate FULC as an investment opportunity.
Fulcrum Therapeutics to Participate at the Cantor Fitzgerald Global Healthcare ConferenceCAMBRIDGE, Mass., Sept. 22, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will participate in a fireside chat at the Cantor Fitzgerald Global Healthcare Conference, being held in New York, NY on Thursday, September 28, 2023 at 8:35 a.m. ET. The webcast of the presentation will be accessible here and through the Invest |
Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)CAMBRIDGE, Mass., Sept. 15, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that the company granted non-statutory stock options to new employees. Fulcrum granted stock options to purchase shares of the company’s common stock pursuant to the company’s 2022 Inducement Stock Incentive Plan, as amended, or the plan, as an inducement mater |
Fulcrum Announces Completion of Enrollment in the Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)Enrolled 260 patients; topline data expected in the fourth quarter of 2024CAMBRIDGE, Mass., Sept. 07, 2023 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc.® (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that it has completed enrollment in REACH, a Phase 3 clinical trial evaluating losmapimod in patients with FSHD at sites in the United States, Canada, and Europe. “We are very pleased to |
The Zacks Analyst Blog Highlights Regeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum TherapeuticsRegeneron Pharmaceuticals, Gilead Sciences, Novavax, Apellis Pharmaceuticals and Fulcrum Therapeutics are part of the Zacks top Analyst Blog. |
Biotech Stock Roundup: REGN Up on Approval, APLS, NVAX Gain on Updates & MoreRegulatory updates from Regeneron (REGN) and Apellis (APLS) are in focus in the biotech sector. |
FULC Price Returns
| 1-mo | -30.07% |
| 3-mo | 18.69% |
| 6-mo | 68.07% |
| 1-year | -50.98% |
| 3-year | -48.98% |
| 5-year | N/A |
| YTD | -45.05% |
| 2022 | -58.85% |
| 2021 | 51.07% |
| 2020 | -29.63% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...